A Monovalent Fab Affinity-Capture and Elution Bridging Immunoassay Overcomes Rheumatoid Factor Interference while Accurately Detecting Antidrug Antibodies
- 20 July 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 8 (5) , 896-908
Abstract
Background: Rheumatoid factor (RF) consists of autoantibodies that bind the fragment crystallizable (Fc) region of human immunoglobulin G (IgG) and present in sera of rheumatoid arthritis (RA) patients. Immunoassays to detect antidrug antibodies (ADA) in RA patient samples may experience interference due to RF binding and crosslinking Fc regions of the capture and detection antibody reagents. To overcome this interference, a novel Fab affinity-capture and elution (ACE)-bridging immunoassay (Fab ACE-Bridge) was developed with monovalent-recombinant Fab to avoid RF interference. Methods: ACE and ACE-Bridge assays were developed to detect ADA against a therapeutic monoclonal antibody using samples from healthy donors, psoriasis patients, and RA patients. The performance of these assays was compared to a novel Fab ACE-Bridge assay, in which monoclonal antibody was replaced with monovalent Fab. Results: High screening signals in the ACE and ACE-Bridge assays were detected in RA patient samples but not in samples from healthy donors or psoriasis patients. The high screening signals in RA samples did not inhibit to the expected extent in the confirmatory assay, a consistent feature of false-positive screening results. Further investigation revealed RF as the interferent affecting assay performance. Modification of the ACE-Bridge assay by using monovalent Fab eliminated RF interference while allowing for sensitive and drug-tolerant detection of authentic ADA. Conclusions: RF interfered significantly in traditional ACE and ACE-Bridge assays. Implementation of a novel monovalent Fab ACE-Bridge assay overcame RF interference. The use of monovalent Fab is recommended for immunogenicity assays when assessing ADA in RA patient samples.Keywords
This publication has 22 references indexed in Scilit:
- Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibodyJournal of Pharmaceutical and Biomedical Analysis, 2011
- Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeuticsJournal of Immunological Methods, 2010
- Naturally occurring auto-antibodies in homeostasis and diseaseTrends in Immunology, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurementCurrent Opinion in Immunology, 2008
- Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsJournal of Immunological Methods, 2008
- An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drugJournal of Immunological Methods, 2007
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsJournal of Immunological Methods, 2004
- Rheumatoid factor revisitedCurrent Opinion in Rheumatology, 2004
- The rheumatoid factor: An analysis of clinical utilityThe American Journal of Medicine, 1991